Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
Public ClinicalTrials.gov record NCT03158688. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in participants with multiple myeloma who have relapsed after 1 to 3 prior therapies.
Study identification
- NCT ID
- NCT03158688
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 466 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 13, 2017 (Actual)
- Primary completion
- Jul 14, 2019 (Actual)
- Completion
- Apr 15, 2022 (Actual)
- Last update posted
- May 9, 2025
2017 – 2022
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lynn Cancer Center Boca Raton Regional Hospital, Lynn Cancer Institute | Boca Raton | Florida | 33486 | — |
| Emory University Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| University of Chicago Medical Center - Multiple Myeloma Research Consortium | Chicago | Illinois | 60637-6613 | — |
| Fort Wayne Medical Oncology and Hematology | Fort Wayne | Indiana | 46845 | — |
| Hattiesburg Clinic Hematology/Oncology | Hattiesburg | Mississippi | 39401 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| New York Presbyterian Hospital, Weill Cornell Medical College | New York | New York | 10021 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Gabrail Cancer Center, LLC | Dover | Ohio | 44622 | — |
| Charleston Oncology | Charleston | South Carolina | 29414 | — |
| Baylor Charles A Sammons Cancer Center at Dallas | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 102 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03158688, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 9, 2025 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03158688 live on ClinicalTrials.gov.